Parkman Healthcare Partners LLC Invests $12.59 Million in Immunome, Inc. $IMNM

Key Points

• Parkman Healthcare Partners acquired 594,202 Immunome shares worth approximately $12.59 million, representing about 0.52% of the company. Institutional investors collectively own 44.58% of Immunome.
• Immunome’s stock opened at $28.01, near its 52-week high of $30.06, while the company reported a quarterly loss of $0.65 per share—worse than the $0.51 consensus estimate.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” average rating and a $34.64 target price, although insiders sold 682,310 shares worth $15.68 million over the past three months.

Parkman Healthcare Partners LLC bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 594,202 shares of the company's stock, valued at approximately $12,591,000. Parkman Healthcare Partners LLC owned about 0.52% of Immunome as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the company. Allworth Financial LP acquired a new position in Immunome in the second quarter valued at about $25,000. KBC Group NV bought a new stake in Immunome during the first quarter worth about $60,000. BNP Paribas Financial Markets increased its holdings in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Strs Ohio acquired a new stake in shares of Immunome during the fourth quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock valued at $65,000 after acquiring an additional 3,802 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Stock Performance

NASDAQ IMNM opened at $28.01 on Tuesday. The stock has a market capitalization of $3.18 billion, a P/E ratio of -11.07 and a beta of 2.07. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $30.06. The stock has a fifty day moving average of $23.39 and a 200-day moving average of $22.33.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities research analysts forecast that Immunome, Inc. will post -2.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen downgraded Immunome from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Barclays started coverage on Immunome in a report on Thursday, May 28th. They set an "overweight" rating and a $36.00 price target for the company. HC Wainwright reissued a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an "outperform" rating on the stock in a research note on Friday, May 15th. Finally, Truist Financial increased their target price on Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Immunome has an average rating of "Moderate Buy" and an average target price of $34.64.

Insiders Place Their Bets

In other news, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares in the company, valued at $1,263,682.94. The trade was a 64.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director owned 92,211 shares in the company, valued at $2,512,749.75. This represents a 10.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is currently owned by insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source